Literature DB >> 23277128

Study of the association of serotonin transporter triallelic 5-HTTLPR and STin2 VNTR polymorphisms with lithium prophylaxis response in bipolar disorder.

Hema Tharoor1, Ananthapadmanabha Kotambail, Sanjeev Jain, Podila Satya Venkata Narasimha Sharma, Kapaettu Satyamoorthy.   

Abstract

The 5-hydroxy tryptamine transporter (5-HTT) gene has been previously implicated in lithium response, but the roles of the triallelic 5-HTT linked promoter region (5-HTTLPR) and variable number tandem repeats in the second intron [serotonin transporter intron 2 (STin2)] have not been reported. We examined these polymorphisms in 122 patients with bipolar I disorder, among which 49 patients were classified as good responders, 49 as nonresponders, and 24 as partial responders to lithium prophylaxis. We observed significant variation in the genotype frequencies of STin2 polymorphism among the response groups (P=0.02). There was also a significant association of haplotype consisting of the S allele of 5-HTTLPR and 10 repeat allele of STin2 with lithium response (P=0.01) and no such relationship was found with 5-HTTLPR variants. Our data support preliminary information of a possible association of STin2 and its combined effect with 5-HTTLPR variants with lithium response and also suggest that lithium is likely to be more effective for patients carrying 5-HTT polymorphisms associated with reduced transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23277128     DOI: 10.1097/YPG.0b013e32835d6fad

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  11 in total

Review 1.  Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.

Authors:  Gin S Malhi; Tim Outhred
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

Review 2.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 3.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 4.  Looking Beyond the 5-HTTLPR Polymorphism: Genetic and Epigenetic Layers of Regulation Affecting the Serotonin Transporter Gene Expression.

Authors:  Sandra Iurescia; Davide Seripa; Monica Rinaldi
Journal:  Mol Neurobiol       Date:  2016-12-08       Impact factor: 5.590

Review 5.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 6.  Molecular actions and clinical pharmacogenetics of lithium therapy.

Authors:  Adem Can; Thomas G Schulze; Todd D Gould
Journal:  Pharmacol Biochem Behav       Date:  2014-02-15       Impact factor: 3.533

7.  A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder.

Authors:  T P Hui; A Kandola; L Shen; G Lewis; D P J Osborn; J R Geddes; J F Hayes
Journal:  Acta Psychiatr Scand       Date:  2019-06-30       Impact factor: 6.392

Review 8.  Socio-demographic and clinical predictors of outcome to long-term treatment with lithium in bipolar disorders: a systematic review of the contemporary literature and recommendations from the ISBD/IGSLI Task Force on treatment with lithium.

Authors:  Diane Grillault Laroche; Bruno Etain; Emanuel Severus; Jan Scott; Frank Bellivier
Journal:  Int J Bipolar Disord       Date:  2020-12-16

Review 9.  The Genetics of Response to and Side Effects of Lithium Treatment in Bipolar Disorder: Future Research Perspectives.

Authors:  Fanny Senner; Mojtaba Oraki Kohshour; Safa Abdalla; Sergi Papiol; Thomas G Schulze
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

10.  Serotonin transporter functional polymorphisms potentially increase risk of schizophrenia separately and as a haplotype.

Authors:  Rana Ghamari; Fatemeh Yazarlou; Zahra Khosravizadeh; Atefeh Moradkhani; Elaheh Abdollahi; Fatemeh Alizadeh
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.